Clinical trials: Moderate-to-severe Inflammatory Bowel Disease
Ulcerative Colitis (UC), Severe Ulcerative Colitis
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body…
- Conditions
- Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
- Trial name
- ASCENTRA-UC (NCT07845487)
- Testing
- PALI-2108
- Where
- 115 sites in United States, Canada and 10 more
- Volunteers
- 204 people
- Sponsor
- Palisade Bio
Ulcerative Colitis
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative colitis is characterized by abnormal activation of, and damage to, the colon epithelium, which is considered to be a central pathogenic mechanism.
- Trial name
- NCT00727324
- Testing
- bovine intestinal alkaline phosphatase (BIAP)
- Where
- 11 sites in Czechia, Italy
- Volunteers
- 22 people
- Sponsor
- AM-Pharma
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective risankizumab is in treating moderately to severely active CD in real world.
- Trial name
- APPRISE (NCT05841537)
- Where
- 154 sites in Austria, Canada and 9 more
- Volunteers
- 1,019 people
- Sponsor
- AbbVie
Ulcerative Colitis
Hyperbaric Oxygen for Ulcerative Colitis
The investigators aim to prospectively study the feasibility and clinical impact of hyperbaric oxygen therapy in acute hospitalized moderate to severe ulcerative colitis flares as an adjunct to standard medical treatment.
- Trial name
- NCT02144350
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Granulomatous Colitis, Crohn's Disease
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
- Conditions
- Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
- Trial name
- NCT03599622
- Testing
- BMS-986165
- Where
- 259 sites in United States, Australia and 24 more
- Volunteers
- 239 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever.
- Trial name
- AIM-CD (NCT05068284)
- Testing
- ABBV-154
- Where
- 166 sites in United States, Australia and 22 more
- Volunteers
- 176 people
- Sponsor
- AbbVie
Crohn Disease
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.
- Trial name
- TRIDENT (NCT02877134)
- Testing
- JNJ-64304500, Ustekinumab
- Where
- 147 sites in United States, Belgium and 12 more
- Volunteers
- 388 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT03627052
- Testing
- Itacitinib
- Sponsor
- Incyte Corporation
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
- Trial name
- LUCENT-URGE (NCT05767021)
- Testing
- Mirikizumab
- Where
- 120 sites in United States, Belgium and 8 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Crohn Disease
VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.
- Trial name
- Harmony-CD (NCT05688852)
- Testing
- VTX958
- Where
- 105 sites in United States, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Ventyx Biosciences, Inc
Ulcerative Colitis
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06257875
- Testing
- Lutikizumab, Adalimumab
- Where
- 191 sites in United States, Australia and 28 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Ulcerative Colitis (UC)
A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis
The goal of this clinical trial is to learn if BB-TL1A-VIAL-HLE is safe in healthy adults and is safe and effective in treating adults with moderate-to-severe ulcerative colitis.
- Trial name
- NCT07029971
- Testing
- BB-TL1A-VIAL-HLE
- Where
- 2 sites in Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vial Australia Pty Ltd
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly GS-4875) compared with placebo control in achieving clinical remission per modified Mayo Clinic Score (MCS) in adults with moderately to…
- Trial name
- Falcon (NCT04130919)
- Testing
- Tilpisertib
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Crohn's Disease
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo…
- Trial name
- NCT00615199
- Testing
- CP-690,550
- Where
- 72 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Pfizer
Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's…
- Trial name
- NCT06045754
- Testing
- Vedolizumab, Adalimumab, Ustekinumab
- Where
- 48 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Takeda
Ulcerative Colitis, IBD
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by…
- Trial name
- Expedition (NCT03616821)
- Testing
- Brazikumab
- Where
- 125 sites in United States, Canada and 17 more
- Volunteers
- 242 people
- Sponsor
- AstraZeneca
Crohn Disease
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe…
- Trial name
- NCT03905109
- Testing
- ABX464
- Where
- Belgium
- Sponsor
- Abivax S.A.
Colitis, Ulcerative
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources.
- Trial name
- NCT01240915
- Testing
- MultiStem low dose, MultiStem high dose
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Colitis, Ulcerative
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative…
- Trial name
- GENIUS (NCT07302360)
- Where
- 11 sites in China
- Volunteers
- 200 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.